The Golden Lounge

[P2O I'm from MO]

CEO interviewed on CNBC this am... the market was expecting 50% with the first test and the 'product' only does ~42% which is still significant considering it's comparison to cervical cancer pre-screening capabilities. The uncertainty is probably due to whether it will offset the income doctors receive from recommending colonoscopy procedures now. If it's significantly less than there won't be a significant push by doctors, even though it provides a much earlier detection rate.